Yingjie Guo

1.1k total citations
39 papers, 957 citations indexed

About

Yingjie Guo is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Yingjie Guo has authored 39 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 15 papers in Oncology and 14 papers in Pharmacology. Recurrent topics in Yingjie Guo's work include Pharmacogenetics and Drug Metabolism (13 papers), Drug Transport and Resistance Mechanisms (12 papers) and Pharmacological Effects and Toxicity Studies (7 papers). Yingjie Guo is often cited by papers focused on Pharmacogenetics and Drug Metabolism (13 papers), Drug Transport and Resistance Mechanisms (12 papers) and Pharmacological Effects and Toxicity Studies (7 papers). Yingjie Guo collaborates with scholars based in China, United States and Saint Kitts and Nevis. Yingjie Guo's co-authors include Hui Zhou, Dayong Si, Limei Zhao, Yubin Ge, Xiaoyan Chen, Dafang Zhong, Cheng Hu, Feng Qiu, HE Xiao-jing and Dafang Zhong and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Yingjie Guo

36 papers receiving 944 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yingjie Guo China 20 352 318 317 230 162 39 957
Yannick Parmentier France 18 265 0.8× 583 1.8× 335 1.1× 259 1.1× 19 0.1× 38 1.1k
Boting Zhou China 18 285 0.8× 223 0.7× 72 0.2× 277 1.2× 261 1.6× 35 848
Pengcheng Wang United States 19 512 1.5× 253 0.8× 246 0.8× 70 0.3× 38 0.2× 39 1.3k
Shuzo Moritani Japan 13 274 0.8× 389 1.2× 71 0.2× 239 1.0× 46 0.3× 19 783
Zubida M. Al‐Majdoub United Kingdom 17 237 0.7× 370 1.2× 307 1.0× 154 0.7× 23 0.1× 44 812
Brigitte Gerin Belgium 7 226 0.6× 132 0.4× 215 0.7× 127 0.6× 116 0.7× 11 761
Takuro Niwa Japan 11 219 0.6× 436 1.4× 188 0.6× 207 0.9× 23 0.1× 16 824
Murali Subramanian India 14 159 0.5× 119 0.4× 179 0.6× 88 0.4× 62 0.4× 43 571
Masahiro Iwaki Japan 18 271 0.8× 304 1.0× 268 0.8× 91 0.4× 15 0.1× 71 924
Timo Korjamo Finland 17 310 0.9× 373 1.2× 170 0.5× 134 0.6× 13 0.1× 29 1.0k

Countries citing papers authored by Yingjie Guo

Since Specialization
Citations

This map shows the geographic impact of Yingjie Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingjie Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingjie Guo more than expected).

Fields of papers citing papers by Yingjie Guo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yingjie Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingjie Guo. The network helps show where Yingjie Guo may publish in the future.

Co-authorship network of co-authors of Yingjie Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Yingjie Guo. A scholar is included among the top collaborators of Yingjie Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yingjie Guo. Yingjie Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Xu, Yichen, et al.. (2025). The antitumor effects and apoptotic mechanism of 20(S)-Protopanaxadiol in acute myeloid leukemia. Journal of Ginseng Research. 49(3). 306–314. 1 indexed citations
3.
Wang, Yishan, Xiaodi Zhang, Jiawei Li, et al.. (2021). Sini Decoction Ameliorates Colorectal Cancer and Modulates the Composition of Gut Microbiota in Mice. Frontiers in Pharmacology. 12. 609992–609992. 30 indexed citations
4.
Wang, Yani, et al.. (2020). Involvement of CYP2E1-ROS-CD36/DGAT2 axis in the pathogenesis of VPA-induced hepatic steatosis in vivo and in vitro. Toxicology. 445. 152585–152585. 22 indexed citations
5.
Gu, Jingkai, et al.. (2020). Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats. Biochemical Pharmacology. 180. 114142–114142. 9 indexed citations
6.
Liang, Min, et al.. (2015). Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy. Drug Metabolism and Pharmacokinetics. 30(3). 209–213. 31 indexed citations
7.
Chen, Ye, et al.. (2015). Identification of an orally available compound with potent and broad FLT3 inhibition activity. Oncogene. 35(23). 2971–2978. 16 indexed citations
8.
Li, Weijing, Min He, Yingjie Guo, et al.. (2013). Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochemical and Biophysical Research Communications. 434(1). 95–101. 65 indexed citations
9.
Zhang, Feng, Cheng Hu, Peng Xue, et al.. (2013). Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Research. 107(3). 231–237. 27 indexed citations
10.
Niu, Xiaojia, Cheng Hu, Hongyi Zhang, et al.. (2013). Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening. Protein Expression and Purification. 92(1). 119–127. 2 indexed citations
11.
Wang, Guan, et al.. (2012). Abstract 1830: Both class I and class II histone deacetylases are required for proliferation and survival of human pancreatic cancer cells. Cancer Research. 72(8_Supplement). 1830–1830. 1 indexed citations
12.
Guo, Yingjie, Cheng Hu, HE Xiao-jing, Feng Qiu, & Limei Zhao. (2012). Effects of UGT1A6, UGT2B7, and CYP2C9 Genotypes on Plasma Concentrations of Valproic Acid in Chinese Children with Epilepsy. Drug Metabolism and Pharmacokinetics. 27(5). 536–542. 78 indexed citations
13.
Liu, Jing‐Yao, Yingjie Guo, Chunkui Zhou, et al.. (2011). Clinical and histopathological features of familial amyloidotic polyneuropathy with transthyretin Val30Ala in a Chinese family. Journal of the Neurological Sciences. 304(1-2). 83–86. 21 indexed citations
14.
Meng, Hongmei, et al.. (2011). Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy & Behavior. 21(1). 27–30. 54 indexed citations
15.
Zhang, Yifan, Dayong Si, Xiaoyan Chen, et al.. (2007). Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. British Journal of Clinical Pharmacology. 64(1). 67–74. 49 indexed citations
16.
Zheng, Qing‐Chuan, Yahong Zhang, Miao Sun, et al.. (2006). On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study. Biochimie. 88(10). 1457–1465. 28 indexed citations
17.
Guo, Yingjie, Ying Wang, Xiaoyan Chen, et al.. (2005). ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANS. Drug Metabolism and Disposition. 33(6). 749–753. 60 indexed citations
18.
Guo, Yingjie, et al.. (2005). Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica. 35(9). 853–861. 42 indexed citations
19.
Zhong, Dafang, et al.. (2004). Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. British Journal of Clinical Pharmacology. 59(1). 14–17. 47 indexed citations
20.
Si, Dayong, et al.. (2004). Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics. 14(7). 465–469. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yannick Parmentier Breakdown of academic impact, for papers by Boting Zhou Breakdown of academic impact, for papers by Pengcheng Wang Breakdown of academic impact, for papers by Shuzo Moritani Breakdown of academic impact, for papers by Zubida M. Al‐Majdoub Breakdown of academic impact, for papers by Brigitte Gerin Breakdown of academic impact, for papers by Takuro Niwa Breakdown of academic impact, for papers by Murali Subramanian Breakdown of academic impact, for papers by Masahiro Iwaki Breakdown of academic impact, for papers by Timo Korjamo
Rankless by CCL
2026